Preparation and properties of 99tcm-exametazime using stannous ion augmentation of fractionated cold kits

Nuclear Medicine Communications

Volumn 20, Issue 3, 1999, Pages 287-294

  Baker, R J ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; TIN; TIN DERIVATIVE; NITROGEN; SODIUM CHLORIDE; STANNOUS PYROPHOSPHATE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; DRUG FORMULATION; DRUG STABILITY; FEMALE; ISOTOPE LABELING; MOUSE; SYNTHESIS; TISSUE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; BRAIN; DRUG DECOMPOSITION; DRUG DISTRIBUTION; DRUG STORAGE; DRUG UPTAKE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; NONHUMAN; SHELF LIFE; TEMPERATURE SENSITIVITY;

ANIMALS; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; INDICATORS AND REAGENTS; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; TECHNETIUM TC 99M EXAMETAZIME; TIN COMPOUNDS; TIN RADIOISOTOPES; TISSUE DISTRIBUTION;

EID: 0032588910     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199903000-00013     Document Type: Article

References (14)

1. Lazarus C, Palmer AL, Hesslewood SR. Radiopharmaceutical kit modification (editorial). Nucl Med Commun 1998; 19; 613-614.
2. Morrisey GJ, Powe, JE. Routine application of fractionated HMPAO stored at-20°C for WBC scintigraphy. J Nucl Med 1993; 34: 151-155.
3. Solanki C, Li DJ, Wong A, Miles KA, Sampson CB. Multidose use of exametazime for leucocyte labelling: A new approach using tin enhancement. Nucl Med Commun 1993; 14: 1035-1040.
4. Solanki C, Li DJ, Wong A, Sampson C. Stabilisation of exametazime for leucocyte labelling: A new approach using tin enhancement. In: Martin-Comin J, ed. Radiolabelled blood elements. New York: Plenum Press, 1994: 43-48.
5. Amir R, Hupez P, Binon JP, Van Nerom C, Verbruggen A, Delcourt E. Potential usefulness of stabilisation methods for 99Tcm-HMPAO in cerebral blood flow imaging. Eur J Nucl Med 1993; 20: 848.
6. Salehi N, Nanni M, Gilleece T, Lichtenstein M. How stable is fractionated exametazime (abstract). ANZ Nucl Med 1998; 29: 49.
7. Kumar V, Chu JMG. Kinetic and stability studies of pyrophosphate spiked, subdispensed HMPAO kit stored at-70°C (abstract). J Nucl Med 1996; 37: 83 P.
8. Solanki C, Li DJ, Wong A, Barber RW, Wraight EP, Sampson CB. Stabilisation and multidose use of exametazime for cerebral perfusion studies. Nucl Med Commun 1994; 15: 718-722.
9. Baker RJ. Properties of Tc-99m radiopharmaceuticals prepared from fractionated cold kits utilising a stannous ion augmentation technique (abstract). J Nucl Med 1996; 37 84 P.
10. Cheng KT, Spicer KM, Deshpande RV. Preparation and storage of single dose portions of exametazime: Effects on radiochemical purity after labeling. Am J Hosp Pharm 1992; 49: 1950-1954.
11. Hawkins T, Reeder A, Keavey PM, Thakker S, Hawker R. The long-term stability of reconstituted exametazime: A clinical and laboratory evaluation. Nucl Med Commun 1991; 12: 1045-1055.
12. Chervu LR, Vallabhajosyula B, Mani J, Chun SB, Blaufox MD. Stannous ion quantitation in 99Tcm-radiopharma-ceutical kits. Eur J Nucl Med 1982; 7: 291-293.
13. Tubergen K, Corlija M, Volkert WA, Holmes RA. Sensitivity of technetium-99m-d-/-HMPAO to radiolysis in aqueous solutions. J Nucl Med 1991; 32: 111-115.
14. Hung JC, Corlija M, Volkert WA, Holmes RA. Kinetic analysis of technetium-99m-£i-I-HM-PAO decomposition in aqueous media. J Nucl Med 1988; 29: 1568-1576.